Technology Transfer Offices
Start Ups Life Sciences
Pharm/Biotech Information
Investors Information
home about us and payments contact details links downloads
PhaseIIFace Partners - business development services & BIOnetworks  for the Life Science & Healthcare Industries Business Development Services and BIOnetworks for the Life Science and Healthcare Industries
  contribute a confidential review
join the pharma licensing club
phaseIIface licensing opportunities
BIONetworks ongoing projects
 
 

PhaseIIFace Licensing Opportunities

 

P2F is contracted to manage development strategies and ensure sound patent drafting and prosecution strategies and instigate negotiations with potential partners for the technologies from client universities and not-for-profit institutions listed below. Any potential licensee is free to contact the University directly or to contact P2F enquiries to find out what is available in the life sciences, devices and drug development opportunities which are continuously monitored and added to. There is no finder’s fee or percentage of any future deal payable to P2F through placing any of the technologies with a licensing/collaboration partner.

  1. The University of Bath

    There are currently 12 life science development projects that are in varying stages of development at the university and open to either collaborative or licensing opportunities. Please contact us for further information.                                         

  2. Biologics  For biologics processing and formulation technology also see Glythera.


  3. Further Technologies available for licensing across Europe

    P2F is in contact with a number of non-profit Universities and Reasearch Institutes in the UK and across Europe. We have particular strength in knowledge of the current oncology research community. We would be happy to receive enquiries form industrial partners looking for specific project types or academic skills and find a partner for you. There is no charge for this service.

  4. Leukocyte Tyrosine Kinase / Anaplastic Lymphoma Kinase (ALK) inhibitors Zebrafish Screen
    University of Bath


    There is considerable interest in lipid kinases as targets for screening against compounds for use as therapeutics in oncology. The research groups at the University under Dr Robert Kelsh have considerable experience in using Zebrafish models and have engineered zebrafish embryos that show clear pigment based (iridophores) phenotypes for screening for compound potency in secondary assays. The assays can be run in multi-well plate format. The inventors are looking for sponsorship to develop the assays for HTS.

    PdfMore details can be read in the downloadable poster.

    click to download adobel acrobatGet Adobe Reader